INVIVYD, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
INVIVYD, INC. (IVVD) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $74.35 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2026-03-05
- 2025-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $74.35M.
- 2024-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $91.95M.
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $74.11M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $36.55M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2025-12-31 | $74.35M 10-K · filed 2026-03-05 |
| 2024-12-31 | $91.95M 10-K · filed 2026-03-05 |
| 2023-12-31 | $74.11M 10-K · filed 2025-03-20 |
| 2022-12-31 | $36.55M 10-K · filed 2024-03-28 |
| 2021-12-31 | $0.00 8-K · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |